Some doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures. A higher portion of muscle can also help patients keep weight off for ...

Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals (NYSE:TEVA) said on Tuesday that the U.S. FDA has accepted for review a ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close.

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

Besides the earnings beat, the drugmaker announced another bit of good news that also had the market excited. Regeneron is now a dividend-paying company. The stock has lagged the market over the last ...

(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ® ...

Q4 2024 Earnings Call Transcript February 13, 2025 Alnylam Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

NEW YORK CITY, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Morgan Stanley from $275.00 to $284.00 in a research note issued to investors on Friday,Benzinga reports. Morgan ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been ...